Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day

Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and 
Sepsis Heroes in Honor of World Sepsis Day 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 09/12/13 --  CytoSorbents
Corporation (OTCQB: CTSO), a leading innovator in the use of blood
purification to treat critical illnesses such as sepsis, is a proud
sponsor of both the Global Sepsis Alliance and the Sepsis Heroes
event hosted by the Sepsis Alliance tonight in New York City, in
honor of the second annual World Sepsis Day tomorrow.  
The Global Sepsis Alliance estimates that every three heartbeats,
someone dies of sepsis. Sepsis is the end result of an overzealous
immune response to a severe infection. Without effective therapies
and with delayed diagnosis, sepsis claims more than 8 million deaths
each year, killing patients of all ages, races, ethnicities,
religions, and socio-economic backgrounds despite the widespread use
of antibiotics. 
"CytoSorbents is dedicated to developing new therapies to treat
sepsis. Our European Union-approved blood filter, CytoSorb(R),
targets the prevention or treatment of organ failure -- the leading
cause of death in sepsis," stated Dr. Phillip Chan, CEO of
CytoSorbents. "Unlike any other therapy before it, CytoSorb(R)
attacks sepsis from many different angles. It works to control the
wayward inflammatory response that can lead to organ failure and more
infection. It can also remove many deadly bacterial toxins. And it
helps direct the activated immune system to the site of infection,
and away from healthy organs where it can cause damage, as seen in
animal studies. No other therapy has demonstrated this broad spectrum
approach to treating sepsis and CytoSorb(R) is available now to
critically ill patients in Europe."  
In the past two weeks, CytoSorbents has engaged in multiple events
surrounding World Sepsis Day.  

--  Exhibited at the 6th International Congress of the German Sepsis
    Society in Weimar, Germany, sponsored by the German Sepsis Society,
    where two clinical case report posters and a research poster were
    accepted for presentation, by researchers from hospitals in Linz -
    Austria, Ulm - Germany, and Jena - Germany. The Linz case report was
    selected for an oral presentation and highlighted the successful use
    of CytoSorb(R) with hemodialysis in a dying 36 year old woman with
    end stage liver failure with catastrophic failure of her major organs
    due septic shock from a severe bacterial pneumonia. Despite more than
    a 90% risk of dying, she stabilized with treatment and recovered. The
    clinical case report from Ulm detailed another successful use of
    CytoSorb(R) in a highly unstable 46 year old woman with septic
    shock from a serious yeast blood infection. She went on to recover as
--  Sponsored and participated in the First Annual National German Sepsis
    Summit in Berlin, Germany on September 9, 2013 held by the German
    Federal Minister of Health
--  Sponsored the Sepsis Heroes Dinner in New York City, which will take
    place tonight at the Arena NYC from 7:30-9:00PM EDT, celebrating
    champions of sepsis awareness, including New York State Governor
    Andrew M. Cuomo and many others

"Given our significant focus on sepsis, we are proud to be active
supporters of these worthy organizations and World Sepsis Day,"
stated Dr. Chan. 
About World Sepsis Day
 World Sepsis Day is an initiative of the
Global Sepsis Alliance (GSA) and its founding non-profit members: The
World Federation of Societies of Intensive and Critical Care
Medicine, the World Federation of Pediatric Intensive and Critical
Care Societies, the World Federation of Critical Care Nurses, the
International Sepsis Forum, and the Sepsis Alliance. The goals of
World Sepsis Day are to: 

--  Reduce the incidence of sepsis through effective prevention strategies
--  Increase sepsis survival rates for all population groups around the
--  Provide better access to suitable rehabilitation services for people
--  Increase awareness and understanding of sepsis among healthcare
    professionals and the general public

For more information, visit 
About the Global Sepsis Alliance
 The Global Sepsis Alliance (GSA) is
a non-profit organization supporting the efforts of over 1 million
caregivers in more than 70 countries as they seek to better
understand and combat what many experts believe to be the leading
cause of death worldwide: sepsis. The GSA has rallied the Global
Sepsis Community to elevate public, philanthropic and governmental
awareness, understanding and support of sepsis and to accelerate
collaboration among researchers, clinicians, associated working
groups and those dedicated to supporting them. For more information,
About the German Sepsis Society
 The German Sepsis Society (GSS) is
the primary medical society in Germany whose mission is to educate
and increase public and professional awareness about sepsis. The
organization brings together leaders in sepsis research, diagnostics,
treatment, and education in order to also encourage new research,
recognize valuable scientific contributions, and foster
collaborations to help save lives. A major goal is to support the
rapid implementation of effective sepsis diagnostics and therapies
into the standard of care treatment for sepsis. Members of the GSS
have been heavily involved with SepNet, or the Sepsis Competence
Network, a consortium of hospitals and investigators funded for 10
years by the German Federal Ministry of Education to conduct research
and clinical trials in sepsis. The GSS also initiated the foundation
of the organization, German Sepsis Aid, by people who survived sepsis
and their relatives, to provide assistance, information, and
networking for those whose lives have been touched by sepsis. For
more information, visit 
About the Sepsis Alliance(TM) and Sepsis Heroes Evening
 The Sepsis
Alliance is a charitable organization run by a team of dedicated
laypeople and professionals who share a strong commitment to battling
sepsis. The goal is to raise awareness of sepsis through information
and educational material so it can be detected and treated early
enough that no harm is done. The Sepsis Heroes Evening is an award
reception, being held on World Sepsis Day in New York City, designed
to raise awareness of sepsis and to recognize the unique
contributions of individuals who have committed their time and energy
for the cause. For more information, visit 
About CytoSorbents Corporation 
 CytoSorbents is a critical care
focused therapeutic device company using blood purification to
modulate the immune system - with the goal of preventing or treating
multiple organ failure in life-threatening illnesses. Organ failure
is the cause of nearly half of all deaths in the intensive care unit,
with little to improve clinical outcome. CytoSorb(R), the Company's
flagship product, is approved in the European Union as a safe and
effective extracorporeal cytokine filter, designed to reduce the
"cytokine storm" that could otherwise cause massive inflammation,
organ failure and death in common critical illnesses such as sepsis,
burn injury, trauma, lung injury, and pancreatitis. These are
conditions where the mortality is extremely high, yet no effective
treatments exist. CytoSorbents' purification technologies are based
on biocompatible, highly porous polymer beads that can actively
remove toxic substances from blood and other bodily fluids by pore
capture and surface adsorption. CytoSorbents has numerous products
under development based upon this unique blood purification
technology, protected by 32 issued US patents and multiple
applications pending, including HemoDefend(TM), ContrastSorb,
DrugSorb, and others. Additional information is available for
download on the Company's website: 
Forward-Looking Statements
 This press release includes
forward-looking statements intended to qualify for the safe harbor
from liability established by the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press release
are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ
materially from those anticipated. These statements are based on
management's current expectations and assumptions and are naturally
subject to uncertainty and changes in circumstances. We caution you
not to place undue reliance upon any such forward-looking statements.
Actual results may differ materially from those expressed or implied
by the statements herein. Risk factors are detailed in the Company's
Form 10-K filed with the SEC on April 3, 2013, which is available at 
Company Contact:
CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823 
Investor Contact:
Alliance Advisors, LLC
Alan Sheinwald
(914) 669-0222 
Valter Pinto
(914) 669-0222 x201 
Media Contact:
JQA Partners
Jules Abraham
(917) 885-7378 
Press spacebar to pause and continue. Press esc to stop.